Tags

Type your tag names separated by a space and hit enter

Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial.
Int Clin Psychopharmacol. 2008 Sep; 23(5):243-53.IC

Abstract

The objective of this study was to assess the efficacy, safety, and tolerability of desvenlafaxine (administered as desvenlafaxine succinate) 50 and 100 mg/day for major depressive disorder (MDD). A multicenter, randomized, double-blind, placebo-controlled trial was conducted in Europe and South Africa. Outpatients with MDD received fixed-dose desvenlafaxine (50 or 100 mg/day) or placebo for 8 weeks. The primary efficacy variable was the 17-item Hamilton Rating Scale for Depression total score; secondary measures included Clinical Global Impressions-Improvement scores. The intent-to-treat population included 483 patients: desvenlafaxine 50 mg (n=164), desvenlafaxine 100 mg (n=158), and placebo (n=161). At the last-observation-carried-forward analysis (final evaluation) using analysis of covariance, adjusted mean changes from baseline on the Hamilton Rating Scale for Depression were significantly greater for both desvenlafaxine 50 mg (-13.2; P=0.002) and 100 mg (-13.7; P<0.001) versus placebo (-10.7). Significant differences on the Clinical Global Impressions-Improvement scores were observed for desvenlafaxine 50 mg (P=0.002) and 100 mg (P<0.001) versus placebo. Both doses of desvenlafaxine were generally well tolerated. The most common treatment-emergent adverse events were nausea, dizziness, insomnia, constipation, fatigue, anxiety, and decreased appetite. Fixed doses of desvenlafaxine 50 and 100 mg/day are safe, generally well tolerated, and effective at a clinically relevant level for the treatment of MDD.

Authors+Show Affiliations

University of Ottawa, Institute of Mental Health Research, Ottawa, Ontario, Canada. pboyer@rohcg.on.caNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

18703933

Citation

Boyer, Patrice, et al. "Efficacy, Safety, and Tolerability of Fixed-dose Desvenlafaxine 50 and 100 Mg/day for Major Depressive Disorder in a Placebo-controlled Trial." International Clinical Psychopharmacology, vol. 23, no. 5, 2008, pp. 243-53.
Boyer P, Montgomery S, Lepola U, et al. Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial. Int Clin Psychopharmacol. 2008;23(5):243-53.
Boyer, P., Montgomery, S., Lepola, U., Germain, J. M., Brisard, C., Ganguly, R., Padmanabhan, S. K., & Tourian, K. A. (2008). Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial. International Clinical Psychopharmacology, 23(5), 243-53. https://doi.org/10.1097/YIC.0b013e32830cebed
Boyer P, et al. Efficacy, Safety, and Tolerability of Fixed-dose Desvenlafaxine 50 and 100 Mg/day for Major Depressive Disorder in a Placebo-controlled Trial. Int Clin Psychopharmacol. 2008;23(5):243-53. PubMed PMID: 18703933.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial. AU - Boyer,Patrice, AU - Montgomery,Stuart, AU - Lepola,Ulla, AU - Germain,Jean-Michel, AU - Brisard,Claudine, AU - Ganguly,Rita, AU - Padmanabhan,Sudharshan K, AU - Tourian,Karen A, PY - 2008/8/16/pubmed PY - 2008/10/24/medline PY - 2008/8/16/entrez SP - 243 EP - 53 JF - International clinical psychopharmacology JO - Int Clin Psychopharmacol VL - 23 IS - 5 N2 - The objective of this study was to assess the efficacy, safety, and tolerability of desvenlafaxine (administered as desvenlafaxine succinate) 50 and 100 mg/day for major depressive disorder (MDD). A multicenter, randomized, double-blind, placebo-controlled trial was conducted in Europe and South Africa. Outpatients with MDD received fixed-dose desvenlafaxine (50 or 100 mg/day) or placebo for 8 weeks. The primary efficacy variable was the 17-item Hamilton Rating Scale for Depression total score; secondary measures included Clinical Global Impressions-Improvement scores. The intent-to-treat population included 483 patients: desvenlafaxine 50 mg (n=164), desvenlafaxine 100 mg (n=158), and placebo (n=161). At the last-observation-carried-forward analysis (final evaluation) using analysis of covariance, adjusted mean changes from baseline on the Hamilton Rating Scale for Depression were significantly greater for both desvenlafaxine 50 mg (-13.2; P=0.002) and 100 mg (-13.7; P<0.001) versus placebo (-10.7). Significant differences on the Clinical Global Impressions-Improvement scores were observed for desvenlafaxine 50 mg (P=0.002) and 100 mg (P<0.001) versus placebo. Both doses of desvenlafaxine were generally well tolerated. The most common treatment-emergent adverse events were nausea, dizziness, insomnia, constipation, fatigue, anxiety, and decreased appetite. Fixed doses of desvenlafaxine 50 and 100 mg/day are safe, generally well tolerated, and effective at a clinically relevant level for the treatment of MDD. SN - 0268-1315 UR - https://www.unboundmedicine.com/medline/citation/18703933/Efficacy_safety_and_tolerability_of_fixed_dose_desvenlafaxine_50_and_100_mg/day_for_major_depressive_disorder_in_a_placebo_controlled_trial_ L2 - http://dx.doi.org/10.1097/YIC.0b013e32830cebed DB - PRIME DP - Unbound Medicine ER -